Everolimus

No summary available for this substance.

Everolimus

Everolimus is a derivative of Rapamycin and a potent, selective mTOR inhibitor. It reduces cell proliferation, angiogenesis, and glucose uptake by inhibiting mTORC1. It is used in medicine to prevent organ transplant rejection and to treat certain types of cancer.

Category
Pharmaceutical
Molecular Formula
C53H83NO14
Mechanism of Action
Everolimus works by inhibiting the mammalian target of rapamycin (mTOR), a protein kinase that regulates cell growth, cell proliferation, and cell survival.
Evidence Grade
A

Other Names

  • Afinitor
  • Zortress
  • Certican
  • RAD001

Primary Benefits

  • Prevents organ transplant rejection
  • Treats certain types of cancer
  • Reduces cell proliferation
  • Inhibits angiogenesis

Recommended Dosage

Adults 10 mg once daily
Children Not recommended
Elderly Adjustment may be necessary

Side Effects

  • Stomatitis
  • Infections
  • Rash
  • Fatigue
  • Diarrhea
  • Decreased appetite

Precautions

  • Caution in patients with hepatic impairment
  • Increased risk of infections
  • May cause hyperglycemia and dyslipidemia
  • Risk of non-infectious pneumonitis

Interactions

  • Inhibitors of CYP3A4
  • Inducers of CYP3A4
  • P-glycoprotein substrates

Key References

  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142783/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006196/
272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more
Unlocking Rapamycin's Potential: Longevity, Health Span, and Future Applications 2:40:39 0
“once weekly dosing with everolimus seemed to give similar efficacy with maybe lower potential side effect risk”

No comments yet.

View all comments (0)
333 ‒ Longevity roundtable—the science of aging, geroprotective molecules, & lifestyle interventions
Unlocking Longevity: Advances in Aging Research, Prevention, and Healthspan 1:20 0
“we have this one study using everus that show that gives us a hint that says hey this might actually enhance immune function in people in their mid-60s but we need the follow-up study”

No comments yet.

View all comments (0)
Dr. Peter Attia: Supplements for Longevity & Their Efficacy
Supplements, Lifestyle, and Strategies for Longevity and Optimal Health 19:04 0
“my conviction around mtor is far more based on the experimental data um something that is actually sorely lacking in the NAD story which we'll discuss so the experimental data are far more convincing right which is when you look at the administration of Ramy or its analoges for example ever alus um when you look at the administration of these molecules to organisms that are as close as possible to the species of interest.”

No comments yet.

View all comments (0)
Dr. Peter Attia: Supplements for Longevity & Their Efficacy
Supplements, Lifestyle, and Strategies for Longevity and Optimal Health 1:42:46 0
“Joan manik um and Lloyd klickstein when they published that paper in 2014 using everolimus where they took a group of 65y olds and randomize them to either a placebo or different Doses and dosing schedules of everolimus found an enhanced immunity in response to an influenza vaccine”

No comments yet.

View all comments (0)